Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC

J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1964-1977. doi: 10.1111/jdv.14470. Epub 2017 Sep 24.

Authors

C Dressler¹, S Rosumeck¹, R N Werner¹, G van der Kraaij², P van Lumig³, M Wakkee⁴, P Spuls², A Nast¹

Affiliations

¹ Division of Evidence-Based Medicine, Department of Dermatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
² Department of Dermatology, Academic Medical Center, Amsterdam, The Netherlands.
³ Department of Dermatology, Radboudumc, Nijmegen, The Netherlands.
⁴ Department of Dermatology, Erasmus University, Rotterdam, The Netherlands.

PMID: 28944515
DOI: 10.1111/jdv.14470

No abstract available

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / adverse effects
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Consensus Development Conferences as Topic
Dermatologic Agents / adverse effects
Dermatologic Agents / therapeutic use*
Humans
Practice Guidelines as Topic*
Psoriasis / drug therapy*
Review Literature as Topic
Thalidomide / adverse effects
Thalidomide / analogs & derivatives*
Thalidomide / therapeutic use

Substances

Anti-Inflammatory Agents, Non-Steroidal
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Dermatologic Agents
Thalidomide
secukinumab
apremilast